For research teamsFind studies
Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
77studies shown
Showing 1-25 of 77
TerminatedNCT05518149

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

This study has public registry information. It focuses on depression and currently lists study information in Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Hungary, Italy, Poland, Portugal, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, the United Kingdom, and the United States.

DepressionOtherFrom 18 Years to 74 Years
Countries
Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Hungary, Italy, Poland, Portugal, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Sponsor
Janssen Research & Development, LLC
Condition
Depression
View study
RecruitingNCT07115628

Accelerated TMS for Treatment-Resistant ECT

This study is recruiting. It focuses on depression and currently lists participation information in Belgium.

DepressionDeviceFrom 18 Years to 70 Years
Countries
Belgium
Sponsor
Universitair Ziekenhuis Brussel
Condition
Depression
View study
Active Not RecruitingNCT04337242

Blended Care Versus Face-to-Face Therapy for Depression

This study is active but not recruiting. It focuses on depression and currently lists study information in Belgium.

DepressionBehavioralFrom 18 Years to 65 Years
Countries
Belgium
Sponsor
Universitaire Ziekenhuizen KU Leuven
Condition
Depression
View study
Not Yet RecruitingNCT07422909

Bridging the Gap: Implementing BRIDGES

This study is not yet recruiting. It focuses on depression and currently lists study information in Belgium.

DepressionOtherFrom 12 Years to 19 Years
Countries
Belgium
Sponsor
Université Catholique de Louvain
Condition
Depression
View study
RecruitingNCT05788198

Integrated Depression Care

This study is recruiting. It focuses on depression and currently lists participation information in Belgium.

DepressionOtherFrom 18 Years to 65 Years
Countries
Belgium
Sponsor
University Ghent
Condition
Depression
View study
RecruitingNCT06966401

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, the Netherlands, Poland, Romania, Slovakia, Sweden, the United Kingdom, and the United States.

DepressionOtherOver 18 Years
Countries
Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Netherlands, Poland, Romania, Slovakia, Sweden, United Kingdom, United States
Sponsor
Neurocrine Biosciences
Condition
Depression
View study
RecruitingNCT06963021

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Canada, Finland, Hungary, Latvia, the United Kingdom, and the United States.

DepressionOtherOver 18 Years
Countries
Belgium, Canada, Finland, Hungary, Latvia, United Kingdom, United States
Sponsor
Neurocrine Biosciences
Condition
Depression
View study
RecruitingNCT05862636

Who Fares Best With Mindfulness Meditation

This study is recruiting. It focuses on depression and currently lists participation information in Belgium and the United Kingdom.

DepressionBehavioralOver 18 Years
Countries
Belgium, United Kingdom
Sponsor
Prof. dr. Filip Raes
Condition
Depression
View study
RecruitingNCT06585787

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, and Ukraine.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study
RecruitingNCT07084831

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Austria, Belgium, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, the Netherlands, and Spain.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Austria, Belgium, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Spain
Sponsor
European Group for Research In Schizophrenia
Condition
Schizophrenia
View study
RecruitingNCT06126224

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, the United Kingdom, and the United States.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study
RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, and the United Kingdom.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study